First-line treatment of thyroid eye disease differs around the globe, with teprotumumab the most commonly prescribed treatment in North America and IV steroids most common in Europe, according to a speaker.
According to findings from a joint survey conducted by the American Thyroid Association and European Thyroid Association (ETA), providers had different opinions on first-line therapy for thyroid eye disease based on their country and identified different barriers to teprotumumab-trbw (Tepezza, Horizon Therapeutics) use.
“Teprotumumab has become the treatment of choice in North America